Clinical Trials Logo

Severe Adverse Events clinical trials

View clinical trials related to Severe Adverse Events.

Filter by:
  • None
  • Page 1

NCT ID: NCT05310305 Recruiting - Radiotherapy Clinical Trials

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Start date: March 26, 2022
Phase:
Study type: Observational

This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.

NCT ID: NCT04479553 Recruiting - Adverse Drug Events Clinical Trials

Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.

Start date: August 17, 2020
Phase:
Study type: Observational [Patient Registry]

This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the potential risk factors for its adverse drug reactions.

NCT ID: NCT02239237 Completed - Adverse Drug Events Clinical Trials

Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study

Start date: September 2014
Phase:
Study type: Observational

This registry aims to monitor the safety of Compound Kuh-seng Injection and to identify the potential risk factors for the adverse drug reactions. Compound Kuh-seng Injection is a kind of natural compound injection extracted from herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae.